AI Automated Translation.

Font Size

Share

Special task force launched to crack down on illegal obesity drug sales and imports

Special task force launched to crack down on illegal obesity drug sales and imports

The Ministry of Food and Drug Safety has established a special task force (TF) to intensify crackdowns on the illegal online sale of glucagon-like peptide (GLP)-1 class obesity treatments.

The ministry plans to inspect overseas direct purchases, second-hand transactions between individuals, and sales brokering through social networking services, and will respond strictly with measures such as referrals for investigation and indictments if illegal activities are confirmed.

On Thursday, the Ministry of Food and Drug Safety said that it has formed and is operating a "Special TF on Illegal Sales of Obesity Treatments" to intensify inspections of illegal online sales, brokering, and advertising related to GLP-1 class obesity treatments.

The special TF consists of an online monitoring team, an on-site inspection team, and an investigation team. The ministry's Pharmaceutical Management Division, Biopharmaceutical Quality Control Division, Cyber Investigation Team, and Central Investigation Unit for Hazardous Offenders are participating to carry out tasks ranging from online surveillance to on-site inspections and investigations.

The primary targets of inspection are illegal online sales and brokering or advertising activities that lure consumers by touting dieting and obesity treatment.

This includes introductions to sales sites through cafes and blogs, second-hand transactions between individuals, and posts on SNS that induce one-on-one chats for the purpose of selling obesity treatments.

If the special TF detects illegal sales posts, it plans to immediately request access blocking from bodies such as the Broadcasting Communications Commission.

It will also operate a reporting center so that consumers can directly report facts of illegal sales. Reports can be made by phone or through the online reporting center on the Ministry of Food and Drug Safety's homepage.

The resale or provision of obesity treatments purchased by individuals overseas and brought into the country for personal use is also subject to crackdowns.

The ministry explained that if a product purchased for self-treatment purposes is not used by the purchaser but is resold domestically or given to acquaintances, it constitutes a violation of the Pharmacy Act.

If related illegal activities are confirmed, measures such as referrals for investigation or indictments will be taken. Violations of Articles 44 and 61 of the Pharmacy Act may result in imprisonment for up to five years or a fine of up to 50 million won.

GLP-1 class obesity treatments are pharmaceuticals involved in regulating blood sugar levels and appetite. The ministry said that, as obesity treatments are prescription drugs that must adhere to prescribed dosages and administration methods under a doctor's prescription and a pharmacist's medication guidance, they should not be purchased or distributed through transactions between individuals.

In particular, it emphasized that medications brought in from abroad by individuals for personal use should be prescribed and purchased only in limited cases where they are essential for disease treatment, and that it is desirable to use them within the approved scope according to a doctor's prescription domestically as well.

The ministry plans to continue inspecting illegal online sales and brokering or advertising activities of pharmaceuticals that violate the Pharmacy Act in order to prevent consumer harm and create a safe environment for medication use going forward.

"This article was translated using AI and may differ slightly from the original."